Optimal Macronutrient Intake Trial to Prevent Heart Disease (OMNI Heart)
Note that you will be prompted to log in or register an account
Accession Number
HLB00831119a
Study Type
Clinical Trial
Collection Type
Open BioLINCC Study
See bottom of this webpage for request information
Study Period
2002 - 2008
NHLBI Division
DCVS
Dataset(s) Last Updated
January 24, 2019
Clinical Trial URLs
https://clinicaltrials.gov/ct2/show/NCT00051350
Primary Publication URLs
https://pubmed.ncbi.nlm.nih.gov/16287956/
Consent
Commercial Use Data Restrictions No
Data Restrictions Based On Area Of Research No
Commercial Use Specimen Restrictions No
Non-Genetic Use Specimen Restrictions Based On Area Of Use Yes
Genetic Use Of Specimens Allowed? No
Specific Consent Restrictions
Consent restricts use of biospecimens to non-genetic research related to CVD or nutrition.
Objectives
The objective of this study was to compare the effects of 3 healthy diets, each with reduced saturated fat intake, on blood pressure and serum lipids.
Background
While reduced intake of saturated fat is widely recommended for the prevention of cardiovascular disease (CVD), the type of macronutrient (carbohydrate, protein, or unsaturated fat) that should replace saturated fat was unresolved.
Participants
The trial included 164 total subjects recruited from 2 clinical centers: Johns Hopkins Medical Institutions (Baltimore, MD) and Brigham and Women’s Hospital (Boston, MA). Subjects were generally healthy adults, age ≥30 years with a systolic blood pressure (SBP) 120-159 mm Hg or diastolic blood pressure (DBP) 80-99 mm Hg. This range includes individuals with prehypertension (systolic, 120-139 mm Hg or diastolic, 80-89 mm Hg) and stage 1 hypertension (systolic, 140-159 mm Hg or diastolic, 90-99 mm Hg). Exclusion criteria included diabetes, prior or active CVD, LDL-cholesterol >220 mg/dL, fasting triglycerides >750 mg/dL, weight more than 350lb, taking medication for reduction of blood pressure lipid levels, unwillingness to stop taking vitamin and mineral supplements, and alcoholic intake of more than 14 drinks per week. The mean age of the participants was 53.6 years, 45% were women, and 55% were African American.
Design
Three healthy diets were tested: a carbohydrate-rich diet similar to the DASH diet, a protein rich diet−about half from plants, and a diet rich in unsaturated fat, mostly monosaturated fat. Subjects spent 3 periods of 6 weeks on each diet. There was 2-4 week washout periods in between the diets−subjects ate their own food during these periods. At the beginning of the study there was a run-in period of 6 days, afterwards the subjects were randomized to 1 of the 6 sequences of the 3 diets. All the food during the study was provided by the researchers. The participants came to the study site weekdays for lunch and food for the other two daily meals, snacks, and weekend meals were provided for the participants to take home. Calories were adjusted in order to maintain weight and to avoid confounding effects of weight loss in the study. Potassium and sodium were also maintained during the study.
Conclusions
A healthy diet with partial substitution of carbohydrate with either protein or monosaturated fat can further lower blood pressure, improve lipid levels, and reduce estimated cardiovascular risk.
Publications
Appel LJ, Sacks FM, Carey VJ, Obarzanek E, Swain JF, Miller ER 3rd, Conlin PR, Erlinger TP, Rosner BA, Laranjo NM, Charleston J, McCarron P, Bishop LM; OmniHeart Collaborative Research Group. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. JAMA. 2005 Nov 16;294(19):2455-64.
Furtado JD, Campos H, Sumner AE, Appel LJ, Carey VJ, Sacks FM. Dietary interventions that lower lipoproteins containing apolipoprotein C-III are more effective in whites than in blacks: results of the OmniHeart trial. Am J Clin Nutr. 2010 Oct;92(4):714-22. Epub 2010 Sep 8.
Additional Details
164
Frequency | Percent | |
---|---|---|
26-30 | 3 | 1.83 |
31-35 | 9 | 5.49 |
36-40 | 9 | 5.49 |
41-45 | 13 | 7.93 |
46-50 | 34 | 20.73 |
51-55 | 28 | 17.07 |
56-60 | 29 | 17.68 |
61-65 | 17 | 10.37 |
66-70 | 16 | 9.76 |
71-75 | 2 | 1.22 |
76-80 | 4 | 2.44 |
Frequency | Percent | |
---|---|---|
Male | 91 | 55.49 |
Female | 73 | 44.51 |
Frequency | Percent | |
---|---|---|
African American | 90 | 54.88 |
Non-African American | 74 | 45.12 |
Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. Section 3 of the BioLINCC handbook describes the components of the review process
11/07/2024
| Serum | Plasma | Urine | Total |
---|---|---|---|---|
Screening Visit 3 | 814 | 568 | 1,006 | 2,388 |
Intervention Period 1 Week 4 | 964 | 1,105 | 0 | 2,069 |
Intervention Period 1 Week 6 | 654 | 542 | 1,005 | 2,201 |
Intervention Period 2 Week 4 | 969 | 1,103 | 0 | 2,072 |
Intervention Period 2 Week 6 | 647 | 539 | 982 | 2,168 |
Intervention Period 3 Week 4 | 921 | 1,060 | 0 | 1,981 |
Intervention Period 3 Week 6 | 626 | 521 | 952 | 2,099 |
11/07/2024
| Serum | |
---|---|---|
Total number of subjects | Average volume (ml) per subject | |
Screening Visit 3 | 161 | 6.13 |
Intervention Period 1 Week 4 | 162 | 7.71 |
Intervention Period 1 Week 6 | 162 | 5.39 |
Intervention Period 2 Week 4 | 162 | 7.94 |
Intervention Period 2 Week 6 | 162 | 5.36 |
Intervention Period 3 Week 4 | 158 | 7.70 |
Intervention Period 3 Week 6 | 158 | 5.20 |
| Plasma | |
---|---|---|
Total number of subjects | Average volume (ml) per subject | |
Screening Visit 3 | 161 | 1.88 |
Intervention Period 1 Week 4 | 162 | 6.46 |
Intervention Period 1 Week 6 | 159 | 1.87 |
Intervention Period 2 Week 4 | 162 | 6.38 |
Intervention Period 2 Week 6 | 160 | 1.86 |
Intervention Period 3 Week 4 | 157 | 6.23 |
Intervention Period 3 Week 6 | 157 | 1.79 |
| Urine | |
---|---|---|
Total number of subjects | Average volume (ml) per subject | |
Screening Visit 3 | 143 | 5.91 |
Intervention Period 1 Week 6 | 154 | 5.70 |
Intervention Period 2 Week 6 | 157 | 5.80 |
Intervention Period 3 Week 6 | 150 | 5.87 |
Please note that researchers must be registered on this site to submit a request, and you will be prompted to log in. If you are not registered on this site, you can do so via the Request button. Registration is quick, easy and free.
Resources Available
Specimens and Study DatasetsMaterials Available
- Plasma
- Serum
- Urine
- More Details
Study Documents
Persons using assistive technology may not be able to fully access information in the study documents. For assistance, Contact BioLINCC and include the web address and/or publication title in your message. If you need help accessing information in different file formats such as PDF, XLS, DOC, see Instructions for Downloading Viewers and Players.